Liquid foam gene delivery significantly enhances transfection efficiency and safety, offering a cost-effective alternative to conventional methods.
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors
Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors (NETs), according to final results from